Cited by 410Lymphoma Diagnosis and TreatmentMedical Imaging Techniques and ApplicationsHematological disorders and diagnostics

The DOI matches its Crossref record; 28 of the 30 references it cites were found in a registry or an index.

Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma

Open access

Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Thomas, J., de Groot, T., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L., Verhoef, G.·2002·Annals of Oncology

DOI 10.1093/annonc/mdf256

Open this paper in CoChat — free account Open PDF

Abstract

Background Less than half of all patients with aggressive non-Hodgkin's lymphoma (NHL) are cured with standard chemotherapy. Therefore, it is important to distinguish between responders to standard treatment and non-responders who may benefit from an early change to a more effective therapy. This study was intended to assess the value of a midtreatment fluorine-18 fluorodeoxyglucose positron emission tomography ([(18)F]FDG-PET) scan to predict clinical outcome in patients with aggressive NHL.Patients and methods Seventy newly diagnosed patients with aggressive NHL, who were treated with doxorubicin-containing chemotherapy, underwent a [(18)F]FDG-PET scan at midtreatment. Presence or absence of abnormal [(18)F]FDG uptake was related to progression-free survival (PFS) and overall survival (OS) using Kaplan-Meier survival analysis. Multivariate analysis was performed to evaluate the effect of the International Prognostic Index (IPI) and early [(18)F]FDG-PET findings on PFS and OS.Results At midtreatment, 33 patients showed persistent abnormal [(18)F]FDG uptake and none of these patients achieved a durable complete remission (CR), whereas 37 patients showed a negative scan; 31/37 remained in CR, with a median follow-up of 1107 days. Only 6/37 patients either achieved a partial response or relapsed. Comparison between groups indicated a statistically significant association between [(18)F]FDG-PET findings and PFS (P <1 x 10(-5)) and OS (P <1 x 10(-5)). In multivariate analysis, [(18)F]FDG-PET at midtreatment was a stronger prognostic factor for PFS (P <1 x 10(-7)) and OS (P <9 x 10(-6)) than the IPI (P <0.11 and P <0.03, respectively).Conclusions Early restaging [(18)F]FDG-PET may be used to tailor induction chemotherapy in patients with aggressive NHL.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/annonc/mdf256

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,236
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]
Harris, N. L., Jaffe, E., Stein, H., Pm, B., Jk, C., Cleary, M. L., Delsol, G., Peeters, C., Falini, B., & Gatter, K. C. (1994) · Blood · doi:10.1182/blood.v84.5.1361.1361 · Cited by 6,312
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291402 · Cited by 4,950
Maximum Likelihood Reconstruction for Emission Tomography
Shepp, L. A., & Vardi, Y. (1982) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.1982.4307558 · Cited by 4,429
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.
Cheson, B. D., Horning, S., Coiffier, B., Shipp, M., Fisher, R. I., Connors, J. M., Lister, T., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,210
Whole-Body Positron Emission Tomography Using18F-Fluorodeoxyglucose for Posttreatment Evaluation in Hodgkin’s Disease and Non-Hodgkin’s Lymphoma Has Higher Diagnostic and Prognostic Value Than Classical Computed Tomography Scan Imaging
Jérusalem, G., Beguin, Y. P., Fassotte, M., Najjar, F., Paulus, P., Rigo, P., & Fillet, G. (1999) · Blood · doi:10.1182/blood.v94.2.429 · Cited by 562

Flagged first, then by citations

Show all 30 references

2 of the 30 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

2000, The first international symposium on biology and treatment of aggressive lymphomas. The stagnation seems to be over, Ann Hematol 2001, 80, B1

Sorted by citations

Items 201–300 of 410

Positron emission tomography: current status and future challenges
Lin, M. F., Shon, I. H., & Lin, P. (2010) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2009.02072.x · Cited by 20
The role of FDG ‐ PET imaging as a prognostic marker of outcome in primary mediastinal B‐cell lymphoma
Nagle, S. J., Chong, E. A., Chekol, S. S., Shah, N. N., Nasta, S. D., GLATSTEIN, E. J., Plastaras, J. P., Torigian, D. A., Schuster, S. J., & Svoboda, J. (2014) · Cancer Medicine · doi:10.1002/cam4.322 · Cited by 20
Prognostic Significance of 18 F-fluorodeoxyglucose Positron Emission Tomography in Lymphoma
Weihrauch, M. R., Dietlein, M., Schicha, H., Diehl, V., & Tesch, H. (2002) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819021000040251 · Cited by 20
Early Treatment Response Evaluation in Patients with Diffuse Large B-Cell Lymphoma—A Pilot Study Comparing Volumetric MRI and PET/CT
Wu, X., Dastidar, P., Pertovaara, H., Korkola, P., Järvenpää, R., Rossi, M. E., Kööbi, T., Eskola, H. J., & Kellokumpu‐Lehtinen, P. (2010) · Molecular Imaging and Biology · doi:10.1007/s11307-010-0404-z · Cited by 19
Dose-response relationship in cyclophosphamide-treated B-cell lymphoma xenografts monitored with [18F]FDG PET
Brepoels, L., Saint‐Hubert, M. D., Stroobants, S. G., Verhoef, G. E. G., Balzarini, J. M., Mortelmans, L. A., & Mottaghy, F. M. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1479-0 · Cited by 19
Self-citation
Review. 18F-FDG PET in the diagnosis and follow-up of thyroid malignancy.
AL-NAHHAS, A. M., Khan, S. H., Gogbashian, A., Banti, E., Rampin, L., & Rubello, D. (2008) · PubMed · Cited by 19
Apoptosis Imaging to Monitor Cancer Therapy: The Road to Fast Treatment Evaluation?
Saint‐Hubert, M. D., Bauwens, M., Verbruggen, A., & Mottaghy, F. M. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112799436320 · Cited by 19
18-Fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of ‘indeterminate’ reports
Thomas, A., Gingrich, R., Smith, B. J., Jacobus, L., Ristow, K. M., Allmer, C., Maurer, M. J., Habermann, T. M., & Link, B. K. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190903560198 · Cited by 19
Functional PET Imaging in Cancer Drug Development
Avril, N. E., & PROPPER, D. J. (2007) · Future Oncology · doi:10.2217/14796694.3.2.215 · Cited by 19
The place of positron emission tomography imaging in the management of patients with malignant lymphoma.
Jérusalem, G., & Beguin, Y. P. (2006) · PubMed · Cited by 19
Role of early PET in the management of diffuse large B-cell lymphoma
Michallet, A., Trotman, J., & Tychyj-Pinel, C. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32833d5905 · Cited by 18
Metabolic functional imaging for tumor radiosensitivity monitoring
Belkacémi, Y., Tsoutsou, P. P., Magné, N., Castadot, P., & Azria, D. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.12.002 · Cited by 18
PET and PET/CT in Management of the Lymphomas
Podoloff, D. A., & Macapinlac, H. A. (2007) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2007.05.008 · Cited by 18
Standardization of image quality across multiple centers by optimization of acquisition and reconstruction parameters with interim FDG-PET/CT for evaluating diffuse large B cell lymphoma
Daisaki, H., Tateishi, U., Terauchi, T., Tatsumi, M., Suzuki, K., Shimada, N., Nishida, H., Numata, A., Kato, K., Akashi, K., et al. (2012) · Annals of Nuclear Medicine · doi:10.1007/s12149-012-0676-2 · Cited by 17
Treatment Approach to Newly Diagnosed Diffuse Large B-Cell Lymphoma
Bachy, E., & Salles, G. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.01.001 · Cited by 17
Renewed interest in the role of consolidative radiotherapy in advanced stage diffuse large B-cell lymphoma
Shi, Z., Esiashvili, N., Flowers, C. R., Das, S., & Khan, M. K. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.779687 · Cited by 17
Association of Occupational Pesticide Exposure With Immunochemotherapy Response and Survival Among Patients With Diffuse Large B-Cell Lymphoma
Lamure, S., Carles, C., Aquereburu, Q., Quittet, P., Tchernonog, E., Paul, F., Jourdan, É., Waultier, A., Defez, C., Belhadj, I., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.2093 · Cited by 17
PET Imaging With F-18 Fluorodeoxyglucose for Primary Lymphoma of Bone
Park, Y. H., Choi, S., Ryoo, B., & Kim, H. T. (2005) · Clinical Nuclear Medicine · doi:10.1097/00003072-200502000-00020 · Cited by 17
Utility of interim and end-of-treatment [18F]-fluorodeoxyglucose positron emission tomography–computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma
Huntington, S. F., Nasta, S. D., Schuster, S. J., Doshi, J. A., & Svoboda, J. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1007506 · Cited by 17
FDG PET/CT Response Assessment Criteria for Patients with Hodgkin’s and Non-Hodgkin’s Lymphoma at End of Therapy: A Multiparametric Approach
Metser, U., Mohan, R. M., Beckley, V., Moshonov, H., Hodgson, D. C., & Murphy, G. (2015) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-015-0368-7 · Cited by 17
PET in lymphoma
Collins, C. D. (2006) · Cancer Imaging · doi:10.1102/1470-7330.2006.9013 · Cited by 17
Post-transplant lymphoproliferative disorders: from treatment to early detection and prevention?
Bakker, N. A., & Imhoff, G. W. V. (2007) · Haematologica · doi:10.3324/haematol.11272 · Cited by 17
Investigating the Existence of Quantum Metabolic Values in Non-Hodgkin’s Lymphoma by 2-Deoxy-2-[F-18]fluoro-d-glucose Positron Emission Tomography
Wong, C.-Y. O., Thie, J. A., Parling-Lynch, K. J., Zakalik, D., Wong, R. H., Gaskill, M., Margolis, J., Hill, J., Sukari, A. W., Chundru, S. N., et al. (2006) · Molecular Imaging and Biology · doi:10.1007/s11307-006-0074-z · Cited by 17
Imaging of Non-Hodgkin Lymphomas: Diagnosis and Response-Adapted Strategies
El‐Galaly, T. C., & Hutchings, M. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-13150-4_5 · Cited by 16
Prognostic value of negative interim 2-[18F]-fluoro-2-deoxy-d-glucose PET/CT in diffuse large B-cell lymphoma
Kwon, S. H., Kang, D. R., Kim, J., Yoon, J., Lee, S. J., Jeong, S. H., Lee, H. W., & An, Y. (2015) · Clinical Radiology · doi:10.1016/j.crad.2015.11.019 · Cited by 16
Interim FDG18-PET SUVmax Variation Adds Prognostic Value to Deauville 5-Point Scale in the Identification of Patients with Ultra-High-Risk Diffuse Large B Cell Lymphoma
Duarte, S., Roque, A. I., Saraiva, T., Afonso, C., Marques, B., Lima, C. B., Neves, D., Lai, A. C., Costa, G., Cipriano, A., et al. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.11.009 · Cited by 15
Preclinical Imaging of Therapy Response Using Metabolic and Apoptosis Molecular Imaging
Saint‐Hubert, M. D., Wang, H., Devos, E., Vunckx, K., Zhou, L., Reutelingsperger, C. P. M., Verbruggen, A., Mortelmans, L. A., Ni, Y., & Mottaghy, F. M. (2010) · Molecular Imaging and Biology · doi:10.1007/s11307-010-0412-z · Cited by 15
Self-citation
Tumor Status at 12 Weeks Predicts Survival in Advanced Colorectal Cancer: Findings from NCCTG N9741
Heun, J. M., Grothey, A. F., Branda, M. E., Goldberg, R. M., & Sargent, D. J. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0064 · Cited by 15
Assessment of Correlation Between Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies
Zhu, R., Lü, D., Chu, Y., Chai, A., Green, M. F., Zhang, N., & Jin, J. Y. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0056-x · Cited by 15
Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma
Sparano, J. A., Lee, J. Y., Kaplan, L. D., Ramos, J. C., Ambinder, R. F., Wachsman, W., Aboulafia, D. M., Noy, A., Henry, D. H., Ratner, L., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.243386 · Cited by 15
The role of FDG-PET scanning in assessing lymphoma in 2012
Bodet‐Milin, C., Eugène, T., Gastinne, T., Bailly, C., Gouill, S. L., Dupas, B., & Kraeber‐Bodéré, F. (2013) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2012.12.005 · Cited by 14
Positron emission tomography imaging as a cancer biomarker
Yu, E. Y., & Mankoff, D. A. (2007) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.7.5.659 · Cited by 14
PET/CT in malignant lymphoma: basic information, clinical application, and proposal
Tateishi, U. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1444-3 · Cited by 14
PET/CT: appropriate application in lymphoma.
Wang, X. (2015) · PubMed · doi:10.3978/j.issn.2304-3865.2014.11.05 · Cited by 14
PET-guided treatment for personalised therapy of Hodgkin lymphoma and aggressive non-Hodgkin lymphoma
Phillips, E. H., Iype, R., & Wirth, A. (2021) · British Journal of Radiology · doi:10.1259/bjr.20210576 · Cited by 14
Risk Stratification for Diffuse Large B-Cell Lymphoma by Integrating Interim Evaluation and International Prognostic Index: A Multicenter Retrospective Study
Shi, X., Liu, X., Li, X., Li, Y., Lu, D., Sun, X. L., Li, Y., Hu, S., Zhang, Y., Zhou, X., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.754964 · Cited by 14
Lesion-Based Radiomics Signature in Pretherapy 18F-FDG PET Predicts Treatment Response to Ibrutinib in Lymphoma
Jimenez, J. E., Dai, D., Xu, G., Zhao, R., Li, T., Pan, T., Wang, L., Lin, Y., Wang, Z., Jaffray, D. A., et al. (2022) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004060 · Cited by 14
USEFULNESS OF FDG-PET TO DIAGNOSE INTRAVASCULAR LYMPHOMA WITH ENCEPHALOPATHY AND RENAL INVOLVEMENT
Balkema, C., Meersseman, W., Hermans, G., Stroobants, S. G., Verhoef, G. E. G., Verbeken, E. K., Demaerel, P., & Blockmans, D. (2008) · Acta Clinica Belgica · doi:10.1179/acb.2008.029 · Cited by 14
Self-citation
Advancing Precision Nuclear Medicine and Molecular Imaging for Lymphoma
Wright, C., Maly, J. J., Zhang, J., & Knopp, M. V. (2016) · PET Clinics · doi:10.1016/j.cpet.2016.08.005 · Cited by 14
18F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: a multicenter study
Minamimoto, R., Fayad, L., Vose, J. M., Meza, J. L., Advani, R. H., Hankins, J. H., Mottaghy, F. M., Macapinlac, H. A., Heinzel, A., Juweid, M. E., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05353-9 · Cited by 14
[F-18]-Fluoro-2-deoxy-d-glucose positron emission tomography as a tool for early detection of immunotherapy response in a murine B cell lymphoma model
Chaise, C., Itti, E., Petegnief, Y., Wirquin, E., Copie‐Bergman, C., Farcet, J., Delfau‐Larue, M., Meignan, M. A., Talbot, J., & Molinier‐Frenkel, V. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0265-0 · Cited by 14
Quantitative CT analysis for assessing response in lymphoma
Rahmouni, A. (2005) · Cancer Imaging · doi:10.1102/1470-7330.2005.0037 · Cited by 14
FDG PET/CT Evaluation of Treatment Response in Patients With Recurrent Colorectal Cancer
Shamim, S. A., Kumar, R., Shandal, V., Halanaik, D., Kumar, G., Bal, C. S., & Malhotra, A. (2010) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e3181feeb48 · Cited by 13
Adaptive regulation of glucose transport, glycolysis and respiration for cell proliferation
Toyoda, Y., & Saitoh, S. (2015) · BioMolecular Concepts · doi:10.1515/bmc-2015-0018 · Cited by 13
Carbohydrate restriction in patients with advanced cancer: a protocol to assess safety and feasibility with an accompanying hypothesis
Fine, E. J., Segal-Isaacson, C. J., Feinman, R. D., & Sparano, J. A. (2008) · Community Oncology · doi:10.1016/s1548-5315(11)70179-6 · Cited by 13
Efficacy of Positron Emission Tomography/Computed Tomography in Gastric Mucosa-associated Lymphoid Tissue Lymphoma
Hwang, J. W., Jee, S. R., Lee, S. H., Kim, J. H., Seol, S. Y., & Lee, S. M. (2016) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2016.67.4.183 · Cited by 13
Research on the midterm efficacy and prognosis of patients with diffuse large B-cell lymphoma by different evaluation methods in interim PET/CT
Li, X., Xie, X., Zhang, L., Li, X., Li, L., Wang, X., Fu, X., Sun, Z., Zhang, X., Li, Z., et al. (2020) · European Journal of Radiology · doi:10.1016/j.ejrad.2020.109301 · Cited by 13
Non-Hodgkin lymphoma: retrospective study on the cost-effectiveness of early treatment response assessment by FDG-PET
Moulin-Romsee, G., Spaepen, K., Stroobants, S. G., & Mortelmans, L. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0690-0 · Cited by 13
Self-citation
Clinical and pathological predictors for FDG-PET/CT avidity in patients with marginal zone lymphoma—a retrospective cohort study
Kagan, K. B. T., Guz, D., Buchrits, S., Gurion, R., Vaxman, I., Priss, M., Groshar, D., Catalano, O. A., Sherban, A., Raanani, P., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05683-2 · Cited by 12
Prognostic Systems for Lymphomas
Johnston, A. M., & Salles, G. (2008) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2008.07.012 · Cited by 12
Early 18F‐labeled fluoro‐2‐deoxy‐D‐glucose positron emission tomography scanning in the lymphomas
Coleman, M., & Kostakoglu, L. (2006) · Cancer · doi:10.1002/cncr.22178 · Cited by 12
Early prediction of response to therapy: the clinical implications in Hodgkin’s and non-Hodgkin’s lymphoma
Kostakoğlu, L. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0787-0 · Cited by 12
Indeterminate lesions in cancer imaging
Spencer, J. A. D. (2008) · Clinical Radiology · doi:10.1016/j.crad.2007.11.025 · Cited by 11
El consumo de Lycopersicum esculentum podría aumentar lipoproteínas de alta densidad (HDL) y disminuir el estrés oxidativo a corto plazo
Eva Madrid, A., Darío Vásquez, Z., Fanny Leyton, A., Mandiola-Quililongo, C., & F, J. A. E. (2006) · Revista médica de Chile · doi:10.4067/s0034-98872006000700008 · Cited by 11
Unresolved issues in diffuse large B-cell lymphomas
Murawski, N., Zwick, C., & Pfreundschuh, M. G. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.170 · Cited by 11
Early Identification of Therapeutic Failure in Nonseminomatous Germ Cell Tumors by Assessing Serum Tumor Marker Decline During Chemotherapy: Still Not Ready for Routine Clinical Use
Toner, G. C. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.923 · Cited by 10
The evolving role of F-FDG PET scans in patients with aggressive non-Hodgkin's lymphoma.
Hosein, P. J., & Lossos, I. S. (2010) · PubMed · Cited by 9
Lymphoma Imaging: Nuclear Medicine
Kostakoğlu, L., & Goldsmith, S. J. (2008) · Springer eBooks · doi:10.1007/978-0-387-29346-2_13 · Cited by 9
Management of relapsed diffuse large B-cell lymphoma
Kenkre, V. P., & Smith, S. M. (2008) · Current Oncology Reports · doi:10.1007/s11912-008-0061-4 · Cited by 9
Imaging of the mediastinum in oncology
Lesslie, M. D., Chasen, M. H., & Munden, R. F. (2007) · Applied Radiology · doi:10.37549/ar1479 · Cited by 9
Challenging paradigms in lymphoma treatment
Bendandi, M., Pileri, S. A., & Zinzani, P. L. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh094 · Cited by 9
PET response–guided radiotherapy for advanced DLBCL?
Wirth, A., & Mikhaeel, N. G. (2021) · Blood · doi:10.1182/blood.2020008740 · Cited by 9
Normal and Abnormal Patterns of 18F-Fluorodeoxyglucose PET/CT in Lymphoma
Bar‐Shalom, R. (2007) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2007.05.006 · Cited by 8
Prognostic Value of Bone Marrow F-18 FDG Uptake in Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma
Wang, J., Kim, D., Kang, W. J., & Cho, H. (2019) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-019-00630-w · Cited by 8
It's About Quality, Not Quantity: Qualitative FDG PET/CT Criteria for Therapy Response Assessment in Clinical Practice
Banks, K. P., Peacock, J. G., Gusman, M., & Clemenshaw, M. N. (2020) · American Journal of Roentgenology · doi:10.2214/ajr.19.22642 · Cited by 8
Utility of the PET–CT in the evaluation of early response to treatment in the diffuse large B-cell lymphoma. Preliminary results
Romera, M. C., Cenzano, C. G., Caresia-Aróztegui, A. P., Martin-Comin, J., González-Barca, E. M., Brulles, Y. R., Abufón, A. P., Barba, J. R., Rodríguez-Bel, L., Rossi‐Seoane, S., et al. (2012) · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · doi:10.1016/j.remnie.2012.05.004 · Cited by 8
Time‐course of effects of external beam radiation on [18F]FDG uptake in healthy tissue and bone marrow
Kesner, A., Lau, V. K., Speiser, M., Hsueh, W., Agazaryan, N., DeMarco, J. J., Czernin, J. G., & Silverman, D. H. S. (2008) · Journal of Applied Clinical Medical Physics · doi:10.1120/jacmp.v9i3.2747 · Cited by 8
FDG-PET and PET/CT in Malignant Lymphoma
Reske, S. N. (2008) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-31203-1_8 · Cited by 8
Predictive value of interim PET/CT visual interpretation in the prognosis of patients with aggressive non-Hodgkin’s lymphoma
Liao, C., Qin, Y.-Y., Tan, X., Hu, J., Tang, Q., Rong, Y., Cen, H., & Li, L.-Q. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s154995 · Cited by 8
Positron Emission Tomography/Computed Tomography in the Management of Hodgkin’s Disease and Non-Hodgkin’s Lymphoma
Rodríguez‐Vigil, B., León, N. G., Pinilla, I., Hernández‐Maraver, D., Coya, J., & Curto, L. M. M. (2006) · Current Problems in Diagnostic Radiology · doi:10.1067/j.cpradiol.2006.02.001 · Cited by 8
Dedifferentiated thyroid carcinoma: the imaging role of 18F-FDG PET and non-iodine radiopharmaceuticals
AL-NAHHAS, A. M. (2004) · Nuclear Medicine Communications · doi:10.1097/00006231-200409000-00005 · Cited by 8
Quantification of Local Tumor Response to Fractionated Radiation Therapy for Non-Hodgkin Lymphoma Using Weekly 18F-FDG PET/CT Imaging
Keller, H., Goda, J. S., Vines, D. C., Lockwood, G., & Tsang, R. W. C. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.02.061 · Cited by 7
Therapeutic strategies in elderly and very elderly patients
Soubeyran, P., de Figueiredo, B. H., Soubeyran, I., Mertens, C., & Cazeau, A. L. (2012) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2012.01.009 · Cited by 7
Interim PET Scans in Diffuse Large B-Cell Lymphoma: Is It Ready for Prime Time?
Bolshinsky, M., & Nabhan, C. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.08.020 · Cited by 7
The prognostic value of interim positron emission tomography scans combined with immunohistochemical data in diffuse large B-cell lymphoma.
Fields, P. A., Mikhaeel, N. G., Hutchings, M., van der Walt, J. D., Nunan, T. O., & Sa, S. (2005) · PubMed · Cited by 7
Effect of steroid treatment on the diagnostic yield of baseline 18f-fluorodeoxyglucose positron emission tomography in aggressive B cell lymphoma
Geiger, K. R., Pasvolsky, O., Berger, T., Raanani, P., Shochat, T., Gurion, R., Anati, T., Groshar, D., Gafter‐Gvili, A., & Bernstine, H. (2022) · EJNMMI Research · doi:10.1186/s13550-022-00924-9 · Cited by 7
Midtreatment Evaluation of Lymphoma Response to Chemotherapy by Volume Perfusion Computed Tomography
Spira, D., Grünwald, L., Vogel, W., Sauter, A. W., Spira, S. M., Claussen, C. D., & Horger, M. (2013) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0b013e3182a90ee7 · Cited by 6
Quantitative Whole-Body Diffusion-weighted MRI after One Treatment Cycle for Aggressive Non-Hodgkin Lymphoma Is an Independent Prognostic Factor of Outcome
Paepe, K. N. D., Keerberghen, C.-A. V., Agazzi, G. M., Keyzer, F. D., Gheysens, O. S., Bechter, O. E., Wolter, P., Dierickx, D., Janssens, A. M., Verhoef, G. E. G., et al. (2021) · Radiology Imaging Cancer · doi:10.1148/rycan.2021200061 · Cited by 6
Self-citation
Body Composition in Patients with Follicular Lymphoma: Asso-Ciations between Changes in Radiomic Parameters in Patients Treated with R-CHOP-like and R-B Regimens: LyRa 01F
Esposito, F., Pascale, M. R., Tesei, C., Gigliotti, P. E., Luciano, A., Angeloni, C., Marinoni, M., Meconi, F., Secchi, R., Patanè, A., et al. (2023) · Cancers · doi:10.3390/cancers15040999 · Cited by 6
Primary Gastric Diffuse Large B-cell Lymphoma with Orbital Involvement: Diagnostic Usefulness of 18F-fluorodeoxyglucose Positron Emission Tomography
Iwaya, Y., Takenaka, K., Akamatsu, T., Yamada, Y., Haba, S., Matsuda, K., Nakazawa, H., Muraki, T., Kaneko, Y., Ito, T., et al. (2011) · Internal Medicine · doi:10.2169/internalmedicine.50.5524 · Cited by 6
Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma
Mylam, K. J., Nielsen, A. L., Pedersen, L. M., & Hutchings, M. (2014) · PET Clinics · doi:10.1016/j.cpet.2014.06.001 · Cited by 6
Prognostic value of interim (18)F-FDG-PET in diffuse large B cell lymphoma treated with rituximab-based immune-chemotherapy: a systematic review and meta-analysis.
Zhu, D., Xu, X., Fang, C., Ji, M., Wu, J., Wu, C., & Jiang, J. (2015) · PubMed · Cited by 6
Primary mediastinal B-cell lymphoma – metabolic and anatomical features in 18FDG-PET/CT and response to therapy
Kocurek, A., Małkowski, B., Giza, A., & Jurczak, W. J. (2016) · Współczesna Onkologia · doi:10.5114/wo.2016.61849 · Cited by 6
Persistent positron emission tomography positivity secondary to benign histiocytic proliferation after treatment of Hodgkin lymphoma
Chumsri, S., Tummala, M. K., Khna, A. M., Zhao, X. F., & Rapoport, A. P. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190601140058 · Cited by 6
PET poised to alter the current paradigm for response assessment of non-Hodgkin's lymphoma
Guermazi, A., & Juweid, M. E. (2006) · British Journal of Radiology · doi:10.1259/bjr/31368041 · Cited by 6
Nuclear Medicine Applications in Hemato-Oncology.
Ak, Í., & Gülbaş, Z. (2003) · PubMed · Cited by 6
The Use of Interim 18 F-Fluorodeoxyglucose PET to Guide Therapy in Lymphoma
Araf, S., & Montoto, S. (2013) · Future Oncology · doi:10.2217/fon.13.55 · Cited by 5
The rate of reduction in the maximum standardized uptake value from the initial to the post-R-CHOP therapy in positron emission tomography scan predicts disease progression in diffuse large B cell lymphoma patients
Ishii, Y., Tomita, N., Tateishi, U., Ishiyama, Y., Yamamoto, E. M., Hattori, Y., Hagihara, M., Yamazaki, E., & Ishigatsubo, Y. (2014) · Medical Oncology · doi:10.1007/s12032-014-0880-0 · Cited by 5
Criteria-Based Imaging and Response Evaluation of Lymphoma 20 Years After Cheson: What is New?
Skusa, C., Weber, M. D., Böttcher, S., & Thierfelder, K. M. (2020) · RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · doi:10.1055/a-1091-8897 · Cited by 5
Quantitative evaluation of therapy options for relapsed/refractory diffuse large B-cell lymphoma: A model-based meta-analysis
Li, T., Yu, J., Hou, M., Zha, S., Cheng, Q., Zheng, Q., & Li, L. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106592 · Cited by 5
18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Management of Aggressive Non-Hodgkin's B-Cell Lymphoma
Shelly, M. J., McDermott, S., O’Connor, O. J., & Blake, M. A. (2012) · ISRN Hematology · doi:10.5402/2012/456706 · Cited by 5
Relationship Between the Response to Treatment and the Prognosis of Patients with Aggressive Lymphomas Treated with Chemotherapy Followed by Involved-field Radiotherapy: Radiographic Assessment
Sasaki, S., Shikama, N., Koiwai, K., & Kadoya, M. (2008) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hym142 · Cited by 5
Can Positron Emission Tomography and Computed Tomography Be a Substitute for Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Patients with Hodgkin’s or Non-Hodgkin’s Lymphoma?
Çetin, G., Çıkrıkçıoğlu, M. A., Özkan, T., Karatoprak, C., Ar, M. C., Eşkazan, A. E., Ayer, M., Cerit, A., Gözübenli, K., Uysal, B. B., et al. (2015) · Turkish Journal of Hematology · doi:10.4274/tjh.2013.0336 · Cited by 5
Post-treatment surveillance imaging in lymphoma
Hiniker, S. M., & Hoppe, R. T. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.01.008 · Cited by 5
Optimización de los criterios metabólicos en la valoración pronóstica de los pacientes con linfoma. Estudio multicéntrico
Cozar, M., García-Garzón, J. R., Moragas-Freixa, M., Soler-Peter, M., Massanas, P. B., Sánchez-Delgado, M., Jurado, R. S., Aguilar-Barrios, J. E., Llorens, R. S., & Ferrer-Rebolleda, J. (2017) · Revista Española de Medicina Nuclear e Imagen Molecular · doi:10.1016/j.remn.2017.03.003 · Cited by 5
[18F]Fluorodeoxyglucose Positron Emission Tomography in the Management of Lymphomas
Kostakoğlu, L. (2008) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2008.n.037 · Cited by 5
Discordant response to chemotherapy: An unusual patternof fluoro-deoxy- d -glucose uptake in heavily pre-treated lymphoma patients
Alinari, L., Ambrosini, V., Castellucci, P., Tani, M., Stefoni, V., Nanni, C., Farsad, M., Rubello, D., Franchi, R., Zinzani, P. L., et al. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190600555785 · Cited by 5
18F-Fluorodeoxyglucose PET/CT in Childhood Lymphoma
Kaste, S. C., & Shulkin, B. L. (2006) · PET Clinics · doi:10.1016/j.cpet.2006.04.005 · Cited by 5
Détermination par logique floue des volumes tumoraux en TEP : application au suivi de la radio-immunothérapie des lymphomes
Esnault, J. M., Vermandel, M., Morschhauser, F., Steinling, M., & Huglo, D. G. (2007) · Médecine Nucléaire · doi:10.1016/j.mednuc.2006.12.009 · Cited by 5
Investigation of Dose Minimisation Protocol for18F-FDG PET-CT in the Management of Lymphoma Postchemotherapy Followup
Sonoda, L. I., Sanghera, B., & Wong, W. (2012) · The Scientific World JOURNAL · doi:10.1100/2012/208135 · Cited by 5

Authors: Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Thomas, J., de Groot, T., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L., & Verhoef, G.
Affiliations: Universitair Ziekenhuis Leuven (BE)
Corresponding author: Spaepen, K.
ORCID: Stroobants, S.
Dupont, P.
Vandenberghe, P.
Thomas, J.
Balzarini, J.
Venue: Annals of Oncology
Publisher: Elsevier BV
Published: 2002-09
Volume: 13
Issue: 9
Pages: 1356-1363
ISSN: 0923-7534 (ISSN-L)
DOI: 10.1093/annonc/mdf256
OpenAlex: W1990827442
Cited by: 410
References: 30
Citations by year: 2026: 2 · 2025: 1 · 2023: 3 · 2022: 11 · 2021: 7 · 2020: 6 · 2019: 4 · 2018: 2 · 2017: 15 · 2016: 18 · 2015: 17 · 2014: 14 · 2013: 25 · 2012: 25
FWCI: 12.74
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 6337 d)
Locations: Annals of Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: Fonds Wetenschappelijk Onderzoek
Topics: Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Health Sciences › Medicine › Hematology › Hematological disorders and diagnostics
Keywords: aggressive non-Hodgkin lymphoma, 18F-FDG PET, treatment response prediction, progression-free survival, overall survival, International Prognostic Index, complete remission, prognostic factors, treatment response monitoring
MeSH terms: Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Child, Child, Preschool, Cyclophosphamide, Doxorubicin, Evaluation Studies as Topic, Female, Humans, Lymphoma, Non-Hodgkin, Male, Middle Aged, Monitoring, Physiologic, Neoplasm Staging, Predictive Value of Tests, Prednisolone, Probability, Prognosis, Prospective Studies, Sensitivity and Specificity, Time Factors, Tomography, Emission-Computed, Vincristine, Survival Rate, Multivariate Analysis, Treatment Outcome, Fluorodeoxyglucose F18

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks